At the beginning of the SARS-CoV-2 pandemic, Genetic Networks mobilized our Sentinel Paradigm Platform powered by GeneScape to identify existing drugs and compounds in development that could be quickly repurposed for treatment of COVID-19.
In less than one month, Genetic Networks identified thirteen drugs / compounds for rapid in vitro testing. Ten of the thirteen were found to have antiviral activity against SARS-CoV2. Remarkably, five of the drugs are now in clinical trials for COVID-19.
To reduce mortality and long-term effects of SARS-CoV2 infection, Genetic Networks is currently working to put these host-directed anti-infective compounds into clinical trials.
